Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Advanced NanotechROCO:6797 +2.65%60 EV-to-EBITDA is 0.10 as of Sep. 07, 2026, which is 78% below its 10-year median of 0.45. GuruFocus rates ROCO:6797 with a GF Score™ of 60/100 and a GF Value™ of NT$16.36 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Taiwan Advanced Nanotech ranks better than 99.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Taiwan Advanced Nanotech's enterprise value is NT$-11.9 Mil.
Taiwan Advanced Nanotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-113.9 Mil. Therefore, Taiwan Advanced Nanotech's EV-to-EBITDA for today is 0.10.
The historical rank and industry rank for Taiwan Advanced Nanotech's EV-to-EBITDA or its related term are showing as below:
ROCO:6797'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -237.92 Med: 0.45 Max: 9.01
Current: 0.1
During the past 9 years, the highest EV-to-EBITDA of Taiwan Advanced Nanotech was 9.01. The lowest was -237.92. And the median was 0.45.
ROCO:6797's EV-to-EBITDA is ranked better than 99.22% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.3
vs ROCO:6797: 0.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Taiwan Advanced Nanotech's PE Ratio (TTM) for today is calculated as:
Taiwan Advanced Nanotech's share price for today is NT$11.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advanced Nanotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-7.264.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6797 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Taiwan Advanced Nanotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advanced Nanotech EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Advanced Nanotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Taiwan Advanced Nanotech's EV-to-EBITDA falls into.
Taiwan Advanced Nanotech's current Enterprise Value is NT$-11.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advanced Nanotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-113.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advanced Nanotech (ROCO:6797) has a EV-to-EBITDA of 0.10 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Taiwan Advanced Nanotech. This is 78% below median its historical median of 0.45. According to the industry distribution chart, Taiwan Advanced Nanotech ranks #4 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 0.8%.
Is Taiwan Advanced Nanotech's EV-to-EBITDA too high?
Taiwan Advanced Nanotech's current EV-to-EBITDA of 0.10 is 78% below median its 10-year median of 0.45. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.30. Taiwan Advanced Nanotech's value of 0.10 is 99.3% below this industry median. Based on the distribution chart, Taiwan Advanced Nanotech ranks #4 out of 516 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Taiwan Advanced Nanotech has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advanced Nanotech's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Taiwan Advanced Nanotech ranks #4 out of 516 companies for EV-to-EBITDA. This places Taiwan Advanced Nanotech in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.30. Taiwan Advanced Nanotech's value of 0.10 is 99.3% below this benchmark. While the company's 10-year median is 0.45 vs. the industry median of 14.30, Taiwan Advanced Nanotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.30, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Advanced Nanotech's current EV-to-EBITDA of 0.10 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Taiwan Advanced Nanotech. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advanced Nanotech's current EV-to-EBITDA is 0.10, which is 78% below median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advanced Nanotech stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech (ROCO:6797) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$16.36, compared to a current price of NT$11.60 — trading 29.1% below its estimated fair value. The current EV-to-EBITDA is 0.10, which is 78% below median its 10-year median of 0.45 and 99.3% below the Medical Devices & Instruments industry median of 14.30. Taiwan Advanced Nanotech's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Taiwan Advanced Nanotech (ROCO:6797), the current EV-to-EBITDA is 0.10 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advanced Nanotech (ROCO:6797) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech stock appears to be undervalued.
The current stock price of NT$11.60 is trading 29.1% below its estimated GF Value™ of NT$16.36.
GuruFocus considers Taiwan Advanced Nanotech to be Modestly Undervalued.
Key valuation signals for ROCO:6797:
EV-to-EBITDA: 0.10 (78% below median its 10-year median of 0.45)
GF Value™: NT$16.36 vs. price of NT$11.60 (29.1% below fair value)
Industry Position: 99.3% below the Medical Devices & Instruments median (#4 of 516)
No single metric tells the full story. See the ROCO:6797 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advanced Nanotech Inc is engaged in development and manufacturing of various functional nanoparticles and automated nucleic acid extraction machines and trading related businesses. With expertise in automation, buffer optimization and modification of magnetic beads, it focuses on offering customer convenient and practical solutions to advance research, life science and molecular diagnostics. It offers various products to meet the requirements of customers. The company's products include Automated Extraction Instruments; Reagent Kit; Mag Nanoparticles; and Consumables.
60GF Score
Get the complete analysis for ROCO:6797
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6797 has been successfully added to your 
